Can-Fite BioPharma (NYSE: CANF) announced favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE